Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA ’s new drug review programs

FDA ’s 5 guidance documents provide details for drug development for neurological conditions such as ALS and Alzheimer’s disease

Source: Food and Drug Administration - February 15, 2018 Category: American Health Source Type: news